Clinical Trial: A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06894771) titled 'A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)' on March 03.

Brief Summary: The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.

Study Start Date: April 02

Study Type: INTERVENTIONAL

Condition: Malignant Neoplasm

Intervention: BIOLOGICAL: MK-4700

Administered via subcutaneous ...